The Kolling Institute Research Strategy was launched at the end of February, setting the strategic framework for the next five years and Kolling unveils new research strategy
broadening opportunities to achieve high-quality translational research.
Kolling Institute Executive Director Professor Carolyn Sue
Three research priority areas were identified during the formation of the strategy: musculoskeletal, neuroscience and pain, and cardiovascular and renal research. Kolling Institute Executive Director Professor Carolyn Sue said the areas of research investigate some of the biggest health challenges of our time. “Collectively, they cost the community billions of dollars a year in health, personal and economic costs,” she said. “There is tremendous expertise across these disciplines within the Kolling, with many researchers world renowned in their fields. Our research teams have a track record of success, a unique breadth of skills and knowledge and globally recognised expertise. “By focusing on these areas, we are moving to strengthen our ability to achieve game-changing research
and ultimately improve the health of our community.” A key component of the new strategy is the provision of research enablers, which will be instrumental in providing collaborative opportunities, modern platforms and infrastructure, and diversified funding. The research enablers will focus on the following areas: › Clinical trials and translation › Data and informatics › Research infrastructure and support services › Recruitment and retention. Carolyn said the strategy identifies opportunities for the Kolling to become a national leader in clinical trials and translational practice, building on existing strengths in this area. “Our researchers work within Royal North Shore Hospital, one of Sydney’s
largest tertiary hospitals, with extensive access to patient groups and state-of-the-art facilities,” she said. “This means our teams can directly incorporate scientific discoveries and evidenced-based improvements into patient care. “We expect there will be a greater involvement in industry trials by building on our expertise and reputation as a leader in clinical trials. “The measures incorporated in the new strategy are aimed at assisting teams to increase the impact of their research. “They will provide a robust strategic framework, delivering new opportunities, greater assistance, access to high quality facilities and new partnerships both within and outside the organisation.”
(Back row left to right): Prof Manuela Ferreira, Prof Robyn Ward and Prof Paul Glare (Front row left to right): A/Prof Sarah Glastras and Dr Belinda Di Bartolo
The Kolling Institute’s Renal Research Team
14
NSLHDNEWS | 2021 YEAR IN REVIEW
Made with FlippingBook - professional solution for displaying marketing and sales documents online